New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
10:25 EDTICPT, ICPT, GILD, GILD, GALT, GALTSummer Street's chief scientific officer holds analyst/industry conference call
Chief Scientific Officer Classen provides a tech assessment, along with a discussion of the drug development for NASH (Non-Alcoholic Steatohepatitis) on an Analyst/Industry conference call to be held on January 21 at 11 am.
News For ICPT;GILD;GALT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 6, 2015
16:02 EDTGILDOptions Update; March 6, 2015
Subscribe for More Information
07:52 EDTICPTIntercept volatility elevated as shares trend higher
Intercept overall option implied volatility of 71 compares to its 26-week average of 66 according to Track Data, suggesting large price movement.
March 5, 2015
16:00 EDTGILDOptions Update; March 5, 2015
Subscribe for More Information
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
March 4, 2015
16:34 EDTICPTShareholder suit against Intercept allowed to proceed, Reuters reports
Subscribe for More Information
15:52 EDTICPTShareholder suit against Intercept allowed to proceed, Reuters reports
11:09 EDTICPT, GILDSanofi, Novartis, Shire may be weighing Genfit acquisition, Bloomberg says
Subscribe for More Information
March 3, 2015
07:35 EDTICPTIntercept risk/reward positive, says RBC Capital
RBC Capital believes that Intercept will rally 20% or more if GenFit data, expected to be announced in the second half of March, isn't clean. If the GenFit data is positive, Intercept's stock might drop, but it would probably rebound, since the company would probably reach a deal with the FDA on a Phase III trial of its OCA drug soon thereafter, according to the firm. RBC keeps a $490 price target and Outperform rating on Intercept.
07:08 EDTGILDAmerican Society for Clinical Pharmacology and Therapeutics holds meeting
Subscribe for More Information
March 2, 2015
09:34 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL MNTA CELG TSLA MCD ARUN GILD KO TWTR NFLX
06:13 EDTICPTIntercept reports Q4 EPS ($1.63), consensus ($1.67)
Subscribe for More Information
February 27, 2015
07:37 EDTGILDGilead removed from the short-term buy list at Deutsche Bank
Subscribe for More Information
February 26, 2015
19:09 EDTGILDGilead announces Phase 3 results for once-daily single tablet HIV regimen
Gilead Sciences announced detailed 48-week results from two Phase 3 studies, Studies 104 and 111, evaluating its investigational once-daily single tablet regimen containing tenofovir alafenamide, or TAF, for the treatment of HIV-1 infection in treatment-naÔve adults. A regimen of elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and TAF 10 mg was found to be statistically non-inferior to Gileadís Stribild, containing elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg, based on percentages of patients with HIV-1 RNA levels less than 50 copies/mL. A second analysis found that patients receiving the TAF regimen also had significantly better renal and bone laboratory parameters than those treated with Stribild. The data were presented in two late-breaker presentations at the 22nd Conference on Retroviruses and Opportunistic Infections in Seattle.
15:25 EDTGILDGilead announces 96% SVR12 rate in Phase 3 study of Harvoni
Subscribe for More Information
February 25, 2015
15:30 EDTGILDGilead announces preclincal data on investigational TLR7 agonist
Subscribe for More Information
February 24, 2015
09:35 EDTGILDActive equity options trading on open
Subscribe for More Information
08:07 EDTGALTGalectin to submit SPA to FDA for GR-MD-02 by end of month
Subscribe for More Information
February 23, 2015
16:00 EDTGILDOptions Update; February 23, 2015
Subscribe for More Information
09:39 EDTGILDActive equity options trading on open
Subscribe for More Information
07:16 EDTGILDMylan signs exclusive agreement with Gilead to distribute Solvaldi, Harvoni
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use